Loading
A phase 3 trial of Pamidronate in Multiple myeloma, run by Nordic Myeloma Study Group, completed.
Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month is a phase 3 interventional study registered as NCT00376883 by Nordic Myeloma Study Group, with 500 participants recorded, started 2000-01. Interventions recorded: pamidronate. Conditions recorded: Multiple Myeloma.
Linked to the drug Pamidronate because the registry names it among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pamidronate, Multiple myeloma and the tag pipeline.
Shares Pamidronate, Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Shares Multiple myeloma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/